The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

Dapagliflozin, the type 2 diabetes (T2D) therapy that recently received an indication in heart failure (HF), meets all 3 criteria for managing the condition outlined in an FDA draft guidance for ...

A new study published in The New England Journal of Medicine showed that daily dapagliflozin dramatically reduced the risk of ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

On July 16 2025, the Court of Appeal dismissed AstraZeneca’s appeal and upheld the first instance decision, finding that AstraZeneca’s compound ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

Dapagliflozin may exert a protective effect on kidney function in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease (ADPKD) when used in conjunction ...

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

Kato E, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus based on ejection fraction [published online March 18, 2019]. Circulation. Verma S, McMurray JJV.

Dapagliflozin was well tolerated among patients with an eGFR of less than 60 mL/minute per 1.73² and among those with an eGFR of greater than or equal to 60 mL/minute per 1.73².